Skip to main content

Table 4 Efficacy of diverse p53 expression status

From: Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study

p53

Pathological efficacy

Clinical efficacy

Total, n(%)

tpCR, n(%)

bpCR, n(%)

CR, n(%)

PR, n(%)

SD, n(%)

Positive

36(66.67)

39(65.00)

14(56.00)

47(55.95)

2(66.67)

63(56.25)

Negative

18(33.33)

21(35.00)

11(44.00)

37(44.05)

1(33.33)

49(43.75)

χ2

4.598

4.021

0.001

0.012

0.000

 

P

0.032

0.045

0.977

0.912

1.000

 
  1. tpCR total pathologic complete response, bpCR breast pathologic complete response, CR complete response, PR partial response, SD stable disease